Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Hernan Schmidt

Psychiatry Eugene, OR Medical Doctor

NPI 1821139494 CMS profile 219040

1258 High St, Eugene, OR 97401

Open in the dashboard

General payments

$7,798

350 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Hernan Schmidt of Eugene, OR is reported in the CMS Open Payments database as having received $7,798 across 350 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,396 87
2024 General $1,946 81
2023 General $1,319 59
2022 General $606 33
2021 General $585 34
2020 General $338 21
2019 General $608 35

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hernan Schmidt
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Hernan Schmidt were reported at $2,396. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Hernan Schmidt Psychiatry median Middle half National median
2019 $608 $184 $59–$605 $163
2020 $338 $119 $36–$372 $114
2021 $585 $143 $43–$576 $132
2022 $606 $153 $50–$590 $149
2023 $1,319 $170 $56–$651 $160
2024 $1,946 $179 $57–$673 $164
2025 $2,396 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Otsuka America Pharmaceutical, Inc. $1,458 72 payments
  2. Janssen Pharmaceuticals, Inc $1,165 45 payments
  3. Teva Pharmaceuticals USA, Inc. $962 47 payments
  4. AbbVie, Inc. $846 41 payments
  5. Axsome Therapeutics, Inc. $813 27 payments
  6. Vanda Pharmaceuticals Inc. $547 28 payments
  7. E.R. Squibb & Sons, L.L.C. $437 13 payments
  8. Eisai Inc. $287 13 payments
  9. Allergan Inc. $202 12 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $193 12 payments
  11. Other $888 40 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,720 345 payments
  2. Education $78 5 payments
Products named General payments · program years 2019–2025
  1. REXULTI $1,158 63 payments
  2. INVEGA SUSTENNA $886 35 payments
  3. Auvelity $813 27 payments
  4. VRAYLAR Neuroscience $667 35 payments
  5. FANAPT $547 28 payments
  6. Austedo XR $543 26 payments
  7. AUSTEDO $419 21 payments
  8. VRAYLAR Neuroscience $368 17 payments
  9. HETLIOZ $359 15 payments
  10. Leqembi $274 12 payments
  11. Other $2,924 132 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

423

Median for Psychiatry & Neurology: 100

Drug cost

$50,578

Median for Psychiatry & Neurology: $2,986

Branded share of claims

5.7%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Invega Sustenna Paliperidone Palmitate Brand 12 $41,914
Gabapentin Generic 91 $2,185
Lurasidone Hcl Generic 11 $917
Quetiapine Fumarate Generic 43 $915
Methylphenidate Hcl Generic 21 $847
Hydroxyzine Hcl Generic 13 $561
Buspirone Hcl Generic 23 $524
Lamotrigine Generic 35 $521
Propranolol Hcl Er Propranolol Hcl Brand 12 $472
Escitalopram Oxalate Generic 24 $343

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
INVEGA SUSTENNA
  • Janssen Pharmaceuticals, Inc $309
$309 12 —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $233
$233 — —
NUEDEXTA
  • Otsuka America Pharmaceutical, Inc. $193
$193 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $145
  • Otsuka Pharmaceutical Development & Commercialization, Inc. $25
$170 — —
COBENFY
  • E.R. Squibb & Sons, L.L.C. $170
$170 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

350 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record